The publication of Fespixon’s Phase 3 data and mechanism of action is an acknowledgement by the JAMA Network Open on its clinical and scientific evidence. The open access online will increase the understanding of Fespixon’s efficacy by the international diabetic foot ulcer (DFU) specialists and also raise the global profile of the new drug. It is hoped that this will benefit the global DFU patients. More details please refer to the link below.